# Evandro de Azambuja

Source: https://onco.cc/people/evandro-de-azambuja/  
OnCo record `evandro-de-azambuja` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Evandro de Azambuja is a breast oncologist who studies heart safety of HER2-targeted therapy in BIG trials.

## Summary

Evandro de Azambuja is Head of the Medical Support Team at Institut Jules Bordet in Brussels and a medical oncologist working with the Breast International Group (BIG). His specialisms are breast cancer, cardio-oncology and adjuvant HER2 therapy. He works on adjuvant HER2 trials and the cardiac safety of trastuzumab-based therapy. His papers include the NeoALTTO phase 3 trial of lapatinib with trastuzumab in HER2-positive early breast cancer and its link between pathological complete response and outcomes, the New England Journal of Medicine report of adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer, and an analysis of trastuzumab-associated cardiac events at long-term follow-up in the HERA trial. His publications are listed on PubMed.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Head of Medical Support Team, Institut Jules Bordet; Medical Oncologist
- Specialisms: Breast cancer; Cardio-oncology; Adjuvant HER2 therapy

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=de%20Azambuja%20E%5BAuthor%5D%20cardiotoxicity%20trastuzumab

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- technologies: [Cardio-oncology](https://onco.cc/technologies/cardio-oncology/)
- companies: [Breast International Group (BIG)](https://onco.cc/companies/big/)
- key papers: [OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer](https://onco.cc/key-papers/paper-olympia-nejm-2021/)
- institutions: [Institut Jules Bordet](https://onco.cc/institutions/institut-jules-bordet/)

---
JSON: https://onco.cc/api/v1/entities/evandro-de-azambuja.json